🔥 We have been featured on Shark Tank India.Episode 13

🔥 We have been featured on Shark Tank India

logologo
Search anything
Ctrl+K
gift
arrow
WhatsApp Icon

Stock Summary and Key Metrics













Investment Checklist




























Forecasts

No ConstituentsNo Constituents

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Ask AI

mockupmockup

Standalone Quarterly Results (in ₹ Crores)

Total Figures
QoQ Changes
Total Figures
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales58762101271051341081028496
Expenses56742121261011321131018298
Operating Profit1.852.71-1.451.183.722.20-4.851.712.64-1.51
OPM %3.203.54-0.690.933.541.64-4.491.673.14-1.57
Other Income0.840.295.141.580.020.687.541.550.794.18
Interest0.410.470.400.470.490.582.481.041.260.92
Depreciation1.271.061.150.961.510.90-1.420.490.690.83
Profit Before Tax1.011.472.151.331.751.401.631.731.480.92
Tax %-21.78-29.93-0.476.778.5748.5770.5520.8131.0838.04
Net Profit1.231.912.151.241.600.720.471.371.020.57
EPS in Rs0.430.670.760.440.560.260.020.480.360.20

Standalone Profit Loss (in ₹ Crores)

Total Figures
YoY Changes
Total Figures
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales396349355300348493419396474449
Expenses386342347297344481411391471446
Operating Profit9.617.647.893.234.65117.724.452.902.78
OPM %2.432.192.221.081.332.311.841.130.610.62
Other Income3.343.184.346.697.012.672.736.969.819.79
Interest4.331.922.231.792.442.042.874.384.664.59
Depreciation0.640.711.010.890.921.991.571.701.941.48
Profit Before Tax7.988.198.997.248.30106.015.346.106.51
Tax %31.3924.5927.2020.0021.5334.6937.2512.3434.0536.10
Net Profit5.476.186.545.796.516.553.774.684.024.16
EPS in Rs2.052.302.302.052.232.311.502.121.281.06
Dividend Payout %0.000.003.570.000.000.000.000.000.00

Standalone Balance Sheet (in ₹ Crores)

Total Figures
YoY Changes
Total Figures
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital17182323232325252828
Reserves2031576369758892105110
Borrowings15103.2416181814383135
Other Liabilities7483864384116117136139117
Total Liabilities125142170146194233245291303291
Fixed Assets7.85121212121414141316
CWIP0.000.000.340.000.000.000.000.000.000.00
Investments0.440.440.440.440.440.400.400.401.382.12
Other Assets117130157133181218230277289272
Total Assets125142170146194233245291303291

Standalone Cash Flows (in ₹ Crores)

Total Figures
YoY Changes
Total Figures
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity5.660.62-200.692.865.480.50-1.28-2.9910
Cash from Investing Activity-2.58-4.96-0.60-1.23-0.92-2.88-3.210.44-1.70-5.94
Cash from Financing Activity-1.633.7523-2.48-1.80-2.452.251.355.58-4.48
Net Cash Flow1.45-0.582.35-3.020.130.15-0.460.510.89-0.12

Documents

Presentations
Concalls
Reports
Presentations

No documents found!

Actions

Action Type




























































AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Ask AI

ai-corner-premiumai-corner-premium
ai-corner-premiumai-corner-premium

Frequently Asked Questions about Aarey Drugs & Pharmaceuticals Ltd

Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) is currently trading at 70.19 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Aarey Drugs & Pharmaceuticals Ltd, founded in 1990, manufactures and supplies pharmaceutical raw materials, chemicals, and API drugs. The company underwent a significant transition in 1993 when the Aarey Group took over and rebranded the company from Niharika Textiles & Chemicals. Aarey Drugs produces pharmaceutical products compliant with IP/BP/CP/USP standards, indicating high-quality assurance and adherence to international regulatory standards. In 2009 and 2016, the company upgraded and diversified its manufacturing capabilities, including new products like Mono Methyl Urea and Erithromycin Derivatives.

Over the past 52 weeks, Aarey Drugs & Pharmaceuticals Ltd has traded between a low of ₹31.30 and a high of ₹100.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Aarey Drugs & Pharmaceuticals Ltd has a market capitalization of approximately 199.84. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Aarey Drugs & Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 66.22 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 199.84 Cr, Aarey Drugs & Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Aarey Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Aarey Drugs & Pharmaceuticals Ltd is 66.22. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.